Recent trends in vaccine development and immunization

Clinics in Dermatology

Volumn 17, Issue 3, 1999, Pages 339-344

  Jaffe, Charles L ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DRUG CARRIER; INACTIVATED VACCINE; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LEISHMANIA VACCINE; LIVE VACCINE; PARASITE ANTIGEN; PLASMID DNA;

CYTOKINE RELEASE; HELPER CELL; HUMAN; IMMUNIZATION; IMMUNOGENICITY; LEISHMANIASIS; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; REVIEW; SKIN LEISHMANIASIS; VACCINATION;

ANIMALS; ANTIGENS, PROTOZOAN; HUMANS; IMMUNIZATION; IMMUNIZATION SCHEDULE; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; MICE; PROTOZOAN VACCINES; PUBLIC HEALTH; WORLD HEALTH;

EID: 0032705645     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(99)00052-8     Document Type: Review

References (54)

1. Peters W., Killick-Kendrick R. The leishmaniasis in biology and medicine. 1987;941 Academic Press, London.
2. Jaffe C.L., Greenblatt C.L. Vaccine development against the intracellular parasite Leishmania. Cryz J.S.J. Vaccines and immunotherapy. 1991;381-403 Pergamon, New York.
3. Greenblatt C.L. Vaccination for leishmaniasis. Chang K.P., Bray R.S. Leishmaniasis. 1985;162-182 Elsevier, Amsterdam.
4. Gicheru M.M., Olobo J.O., Anjili C.O. Heterologous protection by Leishmania donovani for Leishmania major infections in the Vervet monkey model of the disease. Exp Parasitol. 85:1997;109-116.
5. Dube A., Sharma P., Srivastava J.K., et al. Vaccination of langur monkeys (Presbyhtis entellus) against Leishmania donovani with autoclaved L. major plus BCG. Parasitol. 116:1998;219-221.
6. Wenyon C.M. Oriental sore in Baghdad, together with observations on a gregarine in Stegomyia fasciata, the haemogregarine of dogs and the flagellates of house flies. Parasitol. 4:1911;273-344.
7. Gunders A.E. Vaccination past and future role in control . Peters W., Killick-Kendrick R. The leishmaniases in biology and medicine. 1987;929-941 Academic Press, Inc, New York.
8. Altes J., Salas A., Riera M. Visceral leishmaniasis: Another HIV-associated opportunistic infection? Report of eight cases and review of the literature. AIDS. 5:1991;201-207.
9. Desjeux P., Alvar J., Gradoni L., et al. Epidemiological analysis of 692 retrospective cases of Leishmania/HIV co-infections. WHO/LEISH. 96:1998;1-11.
10. Alvar J., Canavate C., Gutierrez-Solar B., et al. Leishmania and human immunodeficiency virus coinfection The first 10 years . Clin Microbiol Rev. 10:1997;298-319.
11. Mattner F., Alber G., Magram J., Kopf M. The role of IL-12 and IL-4 in Leishmania major infection. Adorini L. Chem Immunol. 1997;86-109 Kager, Basel.
12. Louis J., Himmelrich H., Parra-Lopez C., et al. Regulation of protective immunity against Leishmania major in mice. Cur Opi Immunol. 10:1998;459-464.
13. Reiner S.L., Locksley R.M. The regulation of immunity to Leishmania major. Ann Rev Immunol. 13:1995;151-177.
14. Etges R., Muller I. Progressive disease or protective immunity to Leishmania major infection The result of a network of stimulatory and inhibitory interactions . J Mol Med. 76:1998;372-390.
15. Scharton-Kersten T., Scott P. The role of the innate immune response in Th1 cell development following Leishmania major infection. J Leuk Biol. 57:1995;515-522.
16. Allen J.E., Maizels R.M. Th1-Th2 Reliable paradigm or dangerous dogma . Immunol Today. 18:1997;387-392.
17. Genaro O., Toledo V.P.C.Pd., Costa C.Ad., et al. Vaccine for prophylaxis and immunotherapy, Brazil. Clin Dermatol. 14:1996;503-512.
18. Salles-Gomes L. Intra-dermoreaccao de Montenegro na Leishmaniose e outras pesquizas affins. Bras Med. 49:1939;5-15.
19. Bahar K., Dowlati Y., Shidani B., et al. Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. Clin Dermatol. 14:1996;489-495.
20. Dowlati Y., Ehsasi S., Shidani B., et al. Stepwise safety trial of a killed Leishmania vaccine in Iran. Clin Dermatol. 14:1996;497-502.
21. Marzochi K.B., Marzochi M.A., Silva A.F., et al. Phase 1 study of an inactivated vaccine against American tegumentary leishmaniasis in normal volunteers in Brazil. Mem Inst Oswaldo Cruz. 93:1998;205-212.
22. Hommel M., Jaffe C.L., Travi B., Milon G. Experimental models for leishmaniasis and for testing anti-leishmanial vaccines. Ann Trop Med Parasitol. 89:1995;55-73.
23. Eisenberger C.L., Jaffe C.L. Vaccines against leishmaniasis. Levine M.M., Woodrow G.C., Kaper J.B., Cobon G.S. New Generation Vaccines. 2nd ed. 1997;1065-1080 Marcel Dekker, Inc, New York.
24. Mougneau E., Altare F., Wakil A.E., et al. Expression cloning of a protective Leishmania antigen. Science. 268:1995;563-566.
25. Julia V., Rassoulzadegan M., Glaichenhaus N. Resistance to Leishmania major induced by tolerance to a single antigen. Science. 274:1996;421-423.
26. Wilson M.E., Young B.M., Andersen K.P. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infect Imm. 63:1995;2062-2069.
27. Campos-Neto A., Soong L., Cordova J.L. Cloning and expression of a Leishmania donovani gene instructed by a peptide isolated from major histocompatibility complex class II molecules of infected macrophages. J Exp Med. 182:1995;1423-1433.
28. Gonzalez C.R., Noriega F.R., Huerta S., et al. Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana. Vaccine. 16:1998;1043-1052.
29. Connell N.D., Medina-Acosta E., McMaster W.R., et al. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63. Proc Natl Acad Sci USA. 90:1993;11473-11477.
30. Kahl L.P., Lelchuk R., Scott C.A., Beesley J. Characterization of Leishmania major antigen-liposomes that protect BALB/c mice against cutaneous leishmaniasis. Infect Imm. 58:1990;3233-3241.
31. Yang D.M., Fairweather N., Button L.L., et al. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J Immunol. 145:1990;2281-2285.
32. Xu D., Liew F.Y. Protection against leishmaisis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunol. 84:1995;173-176.
33. Frankenburg S., Axelrod O., Kutner S., et al. Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine. Vaccine. 14:1996;923-929.
34. Taubes G. Salvation in a snippet of DNA. Science. 278:1997;1711-1714.
35. Xu D., McSorley S.J., Tetley L., et al. Protective effect on Leishmania major infection of migration inhibitory factor, TNF-α, and IFN-γ administered orally via attenuated Salmonella typhimurium. J Immunol. 160:1998;1285-1289.
36. McSorley S.J., Xu D., Liew F.Y. Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters. Infec Immun. 65:1997;171-178.
37. Lezama-Davila C.M. Vaccination of different strains of mice against cutaneous leishmaniasis Usefulness of membrane antigens encapsulated into liposomes by intraperitoneal and subcutaneous administration . Arch Med Res. 28:1997;47-53.
38. Papadopoulou G., Karagouni E., Dotsika E. ISCOMs vaccine against experimental leishmaniasis. Vaccine. 16:1998;885-892.
39. Scott P., Trinchieri G. IL-12 as an adjuvant for cell-mediated immunity. Sem Immunol. 9:1997;285-291.
40. Sjolander A., Baldwin T.M., Curtis J.M., Handman E. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J Immunol. 160:1998;3949-3957.
41. Xu D., McSorley S.J., Chatfield S.N., et al. Protection against Leishmania major infection in genetically susceptible BALB/c mice by GP63 delivered orally in attenuated Salmonella Typhimurium (AroA- AroD-). Immunol. 85:1995;1-7.
42. Cruz A., Beverley S.M. Gene replacement in parasite protozoa. Nature. 348:1990;171-173.
43. Laban A., Tobin J.F., Lafaille M.A.Cd., Wirth D.F. Stable expression of the bacterial neo, gene in Leishmania enrietti. Nature. 343:1990;572-574.
44. Fonseca A.Ld., Vallochi A.L., Furtado Gd.C., et al. Immune response and protection in mice inoculated with Leishmania amazonensis clones expressing different degrees of virulence. Parasitol Res. 83:1997;690-697.
45. Titus R.G., Gueiros-Filho F.J., Freitas L.A.Rd., et al. Development of a safe live Leishmania vaccine by gene replacement. Proc Natl Acad Sci USA. 92:1995;10267-10271.
46. Gueiros-Filho F.J., Beverley S.M. Selection against the dihydrofolate reductase-thymidylate synthase (DHFR-TS) locus as a probe of genetic alterations in Leishmania major. Mol Cell Biol. 16:1996;5655-5663.
47. Ramsay A.J., Ramshaw I.A., Ada G.L. DNA immunization. Immunolo Cell Biol. 75:1997;360-363.
48. Lipford G.B., Sparwasser T., Bauer M., et al. Immunostimulatory DNA Sequence-dependent production of potentially harmful or useful cytokines . European J Immunol. 27:1997;3420-3426.
49. Sato Y., Roman M., Tighe H., et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 273:1996;352-354.
50. Roman M., Marin-Orozco E., Goodman J., et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nature Med. 3:1997;849-854.
51. Gurunathan S., Sacks D.L., Brown D.R., et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med. 186:1997;1137-1147.
52. Walker R.S., Scharton-Kersten T., Rowton E.D., et al. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Human Gene Ther. 9:1998;1899-1907.
53. Johnston S.A., Sykes K.F., Barry M.A. DNA-based vaccines Extending the technology . Levine M.M., Woodrow G.C., Kaper J.B., Cobon G.S. New Generation Vaccines. 2nd Ed. 1997;279-296 Marcel Dekker, Inc, New York.
54. Armijos R.X., Weigel M.M., Aviles H., et al. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population Safety, immunogenicity, and efficacy during the first 12 months of follow-up . J Inf Dis. 177:1998;1352-1357.